Mixed opinions over push for comparative effectiveness research

Article

One of the most discussed elements of President Obama's health-care reform is the the initiative to launch comparative effectiveness research. The administration contends that CER is about enhancing the quality of care by choosing more effective clinical options. Pharma is worried that comparative effectiveness code for cost-effectiveness, and oncologists are concerned that CER could effect the autonomy of their clinical decision making.

The Obama administration has ponied up $1.1 billion to fund its comparative effectiveness research initiative even though many of the players in the health-care debate do not have a full grasp of how CER will move from concept to a working policy.

In an expression of cautious optimism, 25 of the nation's leading cancer organizations, including ASCO, ACS, and AACR, have signed on to an explanatory report by the Friends of Cancer Research that lays out the tenets of the proposed CER initiative and how it might impact oncology.

However, since the passage of the Medicare Modernization Act in 2003, community oncologists have seen more government oversight and less profits in their practices. Naturally, the confusion surrounding the downstream implications that CER might have on oncology draws concern. In a public statement, Al Benson, MD, co-chair of the group that produced the FOCR report, said, "We as oncologists want to be at the table when CER issues are discussed and funded as we think we can have very positive feedback about critical issues."

The FOCR report is posted at www.FOCR.org.

 

 

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
2 experts are featured in this series.
Related Content